{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:55:03Z","timestamp":1762865703548,"version":"3.37.3"},"reference-count":19,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,2,14]],"date-time":"2008-02-14T00:00:00Z","timestamp":1202947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold>Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.<\/jats:p><jats:p><jats:bold>Aim\u2002<\/jats:bold>To identify an appropriate dosage of renzapride (a 5\u2010HT<jats:sub>4<\/jats:sub>receptor full agonist\/5\u2010HT<jats:sub>3<\/jats:sub>receptor antagonist) to treat abdominal pain\/discomfort in patients with constipation\u2010predominant irritable bowel syndrome.<\/jats:p><jats:p><jats:bold>Methods\u2002<\/jats:bold>In this randomized, placebo\u2010controlled, phase IIb study in the primary care setting, men and women were randomized to placebo or renzapride (1, 2 or 4\u2003mg\/day) for 12\u2003weeks. The primary outcome measure was patient self\u2010assessed relief of abdominal pain\/discomfort during weeks 5\u201312. Secondary efficacy measures included patients\u2019 assessment of their bowel habits, stool consistency and quality of life.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold>Although there were no statistically significant differences between renzapride and placebo for relief from abdominal pain\/discomfort, responder rates in the renzapride treatment groups increased dose dependently, with the 4\u2003mg\/day group being consistently numerically greater than placebo. Importantly, a larger numerical treatment difference vs. placebo was observed in women (8% and 12% respectively). Statistically significant improvements in bowel movement frequency and stool consistency were observed in the 4\u2003mg\/day group relative to placebo. Renzapride was well tolerated at all doses.<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold>This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain\/discomfort in women with constipation\u2010predominant irritable bowel syndrome.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2008.03649.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T14:22:22Z","timestamp":1279894942000},"page":"830-837","source":"Crossref","is-referenced-by-count":35,"title":["Clinical trial: renzapride therapy for constipation\u2010predominant irritable bowel syndrome \u2013 multicentre, randomized, placebo\u2010controlled, double\u2010blind study in primary healthcare setting"],"prefix":"10.1111","volume":"27","author":[{"given":"A. M.","family":"GEORGE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. L.","family":"MEYERS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. I.","family":"HICKLING","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,2,14]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.37095"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035579"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2003.00389.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01094.x"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2005.070789"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90304-X"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0031-6997(25)06935-2","article-title":"Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility","volume":"47","author":"Briejer MR","year":"1995","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00265977"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00391-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02940.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00086-8"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00626-3"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00650.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00081-9"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00400-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01565.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00615.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00629.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7256.259"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2008.03649.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2008.03649.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T08:42:33Z","timestamp":1740300153000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2008.03649.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,14]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1365-2036.2008.03649.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2008.03649.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2008,2,14]]}}}